Investing.com’s stocks of the week
SANTA CLARA, Calif. - HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company with a current market capitalization of approximately $60 million, has announced the pricing of its public offering at $1.70 per share. The company is offering 5,882,353 shares of common stock with the expectation to close the offering around February 14, 2025, depending on market and other conditions. According to InvestingPro data, the stock has experienced an 8.2% decline over the past week, though it maintains a positive 23.8% return over the past year.
The anticipated gross proceeds from the offering are projected to be $10 million, before accounting for the underwriting discount, commissions, and other offering expenses. MDB Capital is serving as the underwriter, while Paulson Investment Company LLC has been involved as a selected dealer. InvestingPro analysis indicates that while HeartBeam holds more cash than debt on its balance sheet, the company is currently experiencing rapid cash burn, making this capital raise particularly significant for its operations.
The capital raised is intended to support HeartBeam's strategic initiatives, which include focusing on significant growth milestones and preparing for the commercialization of its products in the U.S. market. The net proceeds are earmarked for commercial-readiness activities, as well as investments in key research and development, clinical trials, regulatory projects, working capital, and other general corporate purposes.
In addition to the shares offered, HeartBeam has granted the underwriter a 45-day option to purchase up to an additional 882,353 shares to cover any over-allotments.
This offering is being made through a written prospectus and prospectus supplement, part of a registration statement filed with the Securities and Exchange Commission (SEC). These documents are available on the SEC's website.
HeartBeam is known for its efforts to revolutionize cardiac care by developing a cable-free synthesized 12-lead ECG technology. This innovation is expected to enable portable devices to capture the heart's electrical signals from various directions, allowing for actionable heart intelligence to be delivered outside of medical facilities. Analyst targets for the stock range from $2 to $8 per share, reflecting varied expectations about the company's growth potential. For deeper insights into HeartBeam's financial health and growth prospects, investors can access comprehensive analysis and additional ProTips through InvestingPro's detailed research reports, available as part of their coverage of over 1,400 US equities.
The information presented in this article is based on a press release statement from HeartBeam, Inc. and contains forward-looking statements that are subject to risks and uncertainties. These statements are not guarantees of future performance, and actual results may differ materially.
In other recent news, medical technology firm HeartBeam, Inc. has made significant strides in cardiac care technology. The company has submitted a 510(k) application to the U.S. Food and Drug Administration (FDA) for its 12-lead electrocardiogram (ECG) synthesis software. This innovative software is designed to monitor and detect various cardiac rhythms and arrhythmias. The FDA submission is backed by data from the VALID-ECG study involving 198 patients across five clinical sites.
In addition to this, HeartBeam has received 510(k) clearance from the FDA for its novel ECG system aimed at enhancing cardiac care. The company plans to integrate AI-based classification algorithms and detection of heart attacks into its technology, potentially reducing the time between the onset of heart attack symptoms and treatment.
Furthermore, HeartBeam's vector-based technology has shown promise in clinical studies for advancing cardiac care. Results from two studies presented at the American Heart Association's annual Scientific Sessions suggested a high degree of sensitivity and specificity in arrhythmia detection using HeartBeam's synthesized 12-lead ECG waveforms. The company's proprietary algorithm, designed to calculate an acute coronary syndrome risk score, showed consistency with assessments made by Emergency Department physicians.
These are the recent developments in HeartBeam's ongoing efforts to revolutionize cardiac care through its innovative technology.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.